Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Kraft Heinz Co (KHC) Price & Performance

Bio-Rad Laboratories, Inc. Class A Common StockTrade
Kraft Heinz CoTrade

Price performance (Past 24H)

Key statistics

Bio-Rad Laboratories, Inc. Class A Common Stock vs Kraft Heinz Co — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Kraft Heinz Co trades at $24.97 (market cap $29.74B). The key difference: Kraft Heinz Co is far larger — about 3.7× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Kraft Heinz Co pays a 6.38% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.

BIOKHC
Market Cap
$8.04B$29.74B
Sector
HealthConsumer Staples
52-Week High
$339.75$28.94
52-Week Low
$241.71$21.21
Enterprise Value
$7.85B$46.78B
Dividend Yield
6.38%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bio-Rad Laboratories, Inc. Class A Common Stock

BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.

Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.

Kraft Heinz Co

Kraft Heinz (KHC) trades at $25.23, up 1.53% with a bullish technical trend and strong recent earnings beats. The stock shows attractive valuation metrics with a P/E of 13.04 and P/B of 0.71, though profitability remains challenged with negative net income margins. Recent corporate restructuring aims to accelerate growth, while a 6.4% dividend yield provides income support. Cash flow trends have improved significantly from 2022's negative $2.4B to 2025's positive $1.46B.

The outlook remains cautious despite technical strength. While undervaluation and dividend yield offer appeal, persistent negative profitability and high debt levels pose significant risks. Analyst consensus is predominantly Hold with a $23.50 price target below current levels, suggesting limited near-term upside potential amid execution challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Read more on BIO

About Kraft Heinz Co

In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.

Read more on KHC